LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
They are often combined with lifestyle-based interventions for long-term success
Pharm Res 26:24862494 Timmons PB, Hewage CM (2021) Conformation and membrane interaction studies of the potent antimicrobial and anticancer peptide palustrin-Ca
The characteristic light blue appearance of the formulation confirms active copper chelation and proper peptide-copper binding an important quality indicator for research reproducibility
It is one of our most requested combination vials among UK research peptide laboratories
If you want a broader comparison between peptide support and retinoid-style positioning, this Tripeptide-5 vs